Quick Answer
ARROWHEAD PHARMACEUTICALS, INC. reported Stockholders Equity of $466.05 million for fiscal year 2025.
ARROWHEAD PHARMACEUTICALS, INC. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $466.05M | +151.3% |
| 2024 | $185.44M | -31.7% |
| 2023 | $271.34M | -31.9% |
| 2022 | $398.52M | -2.5% |
| 2021 | $408.82M | -11.5% |
| 2020 | $461.78M | +88.8% |
| 2019 | $244.59M | +155.3% |
| 2018 | $95.80M | +17.7% |
| 2017 | $81.42M | -14.8% |
| 2016 | $95.58M | -13.2% |
| 2015 | $110.18M | -33.8% |
| 2014 | $166.54M | +505.6% |
| 2013 | $27.50M | +174.6% |
| 2012 | $10.01M | -21.7% |
| 2011 | $12.79M | +58.3% |
| 2010 | $8.08M | +66.3% |
| 2009 | $4.86M | -60.5% |
| 2008 | $12.30M | -53.5% |
| 2007 | $26.46M | -16.3% |
| 2006 | $31.61M | +12.8% |
| 2005 | $28.03M | +149.6% |
| 2004 | $11.23M | +690.8% |
| 2003 | $1.42M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $568.42M | +980.9% | +22.0% |
| September 30, 2025 | $466.05M | +151.3% | -10.8% |
| June 30, 2025 | $522.31M | +58.0% | -23.6% |
| March 31, 2025 | $683.32M | +41.2% | +1199.4% |
| December 31, 2024 | $52.59M | -67.2% | -71.6% |
| September 30, 2024 | $185.44M | -31.7% | -43.9% |
| June 30, 2024 | $330.55M | -9.4% | -31.7% |
| March 31, 2024 | $483.79M | +8.3% | +201.6% |
- ARROWHEAD PHARMACEUTICALS, INC. showed an increase of +151.3% in Stockholders Equity compared to the prior fiscal year.
- Over the 2003–2025 period, ARROWHEAD PHARMACEUTICALS, INC.’s stockholders equity has grown by 32726.1% (from $1.42 million to $466.05 million).
- The most recent figure is from ARROWHEAD PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on November 25, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: